BRITISH COLUMBIA

FIRAZYR is covered by British Columbia Pharmacare (Special Authorization)

Eligibility

For FIRAZYR to be eligible for coverage by PharmaCare, prescribers must submit a request for Special Authorization and approval must be in place before the patient fills the prescription. Deductibles may apply. For more information concerning the reimbursement process, contact OnePath®.

Reimbursement Criteria

We are pleased to inform you that FIRAZYR (icatibant acetate) is reimbursed in British Columbia for your hereditary angioedema (HAE) patients who meet the following criteria:

Initial:

For the treatment of acute attacks of HAE in adult patients with lab confirmed C1-esterase inhibitor deficiency (type I or type II) who meet ALL of the following criteria:

  • For the treatment of acute laryngeal attacks OR for the treatment of non-laryngeal attacks of at least moderate severity2, AND
  • Patient is limited to a single dose for self-administration per attack3,4, AND
  • Drug is prescribed by a physician experienced in the treatment of HAE

Approval Year: 1 year1

Renewal:

  • Must provide details regarding the patient’s history of attacks, medication utilization, and medical follow-up received for each attack within the last year, AND
  • Patient is limited to a single dose for self-administration per attack3,4, AND
  • Drug is prescribed by a physician experienced in the treatment of HAE

Approval Year: 1 year1

Special Notes:

  1. PharmaCare coverage is limited to a maximum of 24 pre-filled syringes per year.
  2. Non-laryngeal attack of at least moderate severity is defined as cutaneous swellings of the face and/ or neck or abdominal attacks. Cutaneous swellings of areas other than the face, neck, or abdomen are not eligible for PharmaCare coverage.
  3. To minimize drug wastage, patients are limited to a maximum of one pre-filled syringe of icatibant dispensed per prescription fill. Patients should not fill an additional dose of icatibant prior to the utilization of the patient’s existing pre-filled syringe of the drug.
  4. Prophylaxis of HAE attacks is not eligible for PharmaCare coverage.

OnePath® Patient Support Program will help navigate insurance coverage and access reimbursement to medication through private and public insurance companies.

Find Out More

Source: British Columbia PharmaCare. Limited Coverage Drugs Program. Icatibant.
https://www2.gov.bc.ca/gov/content/health/practitioner-professional-resources/pharmacare/prescribers/limited-coverage-drug-program/limited-coverage-drugs-icatibant